Hypertension Prevalence and Control at Trial Entry in the REPRIEVE Study Population: Results From a Secondary Analysis
Open Access
- 20 August 2026
- journal article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (9)
Abstract
Background: We evaluated baseline hypertension prevalence and control and risk of major adverse cardiovascular events (MACEs) among people with HIV in REPRIEVE who had low to moderate traditional cardiovascular disease (CVD) risk. Methods: Hypertension at baseline was defined by (1) a preexisting diagnosis regardless of antihypertensive treatment or (2) systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg without a prior diagnosis. We estimated the prevalence of the composite hypertension and control outcomes and calculated adjusted prevalence ratios controlling for traditional CVD risk factors using log binomial regression. We explored the relationship between hypertension and MACE using cause-specific Cox proportional hazards models. Results: Of 7769 participants enrolled from 5 regions, the median age was 50 years, and 2419 (31%) were women. The prevalence of baseline hypertension was 36% (n = 2780) with geographic variation. Among these, 1911 (69%) individuals had a preexisting hypertension diagnosis; the remainder (n = 869, 31%) were undiagnosed. Region and traditional CVD risk factors were associated with hypertension prevalence, with obese and overweight body mass index having the highest adjusted prevalence ratios (1.80 [95% CI, 1.67–1.95] and 1.38 [95% CI, 1.28–1.49], respectively). Among those with preexisting hypertension, 40% were uncontrolled, with regional variation. Hypertension at baseline was associated with an increased hazard of MACE (hazard ratio, 2.00; 95% CI, 1.57–2.55) and key components of MACE, including myocardial infarction and stroke. Conclusions: Approximately 1 in 3 REPRIEVE participants had hypertension at baseline. Hypertension was frequently suboptimally controlled. These findings highlight the need for improved screening and optimized treatment of hypertension in people with HIV.Keywords
Funding Information
- Norges Idrettshøgskole (U01HL123336)
- Norges Idrettshøgskole (1UG3HL164285)
- Clinical Coordinating Center (U01HL123339)
- Clinical Coordinating Center (1U24HL164284)
- Data Coordinating Center
- Kowa Pharmaceuticals America, Inc
- Gilead Sciences
- ViiV Healthcare (UM1 AI068636)
- Advancing Clinical Therapeutics Globally Leadership and Operations Center (UM1 AI106701)
- ACTG Laboratory Center
- Boston Area Nutrition Obesity Research Center (P30DK040561)
- Instituto de Salud Carlos III (PI24/01386)
- European Regional Development Fund
This publication has 20 references indexed in Scilit:
- Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trialThe Lancet HIV, 2026
- The burden of non-communicable diseases among people living with HIV in Sub-Saharan Africa: a systematic review and meta-analysiseClinicalMedicine, 2023
- Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studiesThe Lancet HIV, 2023
- Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participantsThe Lancet, 2021
- Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)American Heart Journal, 2019
- Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017The Lancet, 2018
- 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in AdultsJACC, 2018
- Global prevalence of hypertension among people living with HIV: a systematic review and meta-analysisJournal of the American Society of Hypertension, 2017
- Meta-Analysis of Cohort Studies of Baseline Prehypertension and Risk of Coronary Heart DiseaseThe American Journal of Cardiology, 2013
- Appropriate body-mass index for Asian populations and its implications for policy and intervention strategiesThe Lancet, 2004